QTTB (Q32 Bio) Pre-Tax Income : $-47.54 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Q32 Bio's pretax income for the three months ended in Dec. 2024 was $-14.17 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-47.54 Mil. Q32 Bio's pretax margin was %.

During the past 4 years, Q32 Bio's highest Pretax Margin was 803.26%. The lowest was -642.72%. And the median was 80.27%.

Q32 Bio Pre-Tax Income Historical Data

The historical data trend for Q32 Bio's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Pre-Tax Income Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

-37.02

-42.75

-53.43

-46.09

Q32 Bio Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial					-26.81	1.21	-16.98	-17.60	-14.17

Competitive Comparison of Q32 Bio's Pre-Tax Income

For the Biotechnology subindustry, Q32 Bio's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Q32 Bio Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Q32 Bio's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-66.102	+	17.215	+	-1.1	+	3.9	+	-7.105427357601E-15
	=	-46.09

Q32 Bio's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-14.526	+	-2.442	+	0	+	0	+	2.8
	=	-14.17

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.54 Mil.

Q32 Bio (NAS:QTTB) Pre-Tax Income Explanation

Q32 Bio's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-14.168	/	0
	=	%

During the past 4 years, Q32 Bio's highest Pretax Margin was 803.26%. The lowest was -642.72%. And the median was 80.27%.

Q32 Bio Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

DB0:Germany

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.